ÂÜÀòÂÒÂ×

Dan Spiegelman is an experienced biotech executive who currently serves as an independent director at Kyverna Therapeutics. Dan has also previously served as the executive vice president and chief financial officer at BioMarin, where they oversaw the company's growth from 3 approved products to 7 approved products and initial profitability. Prior to joining BioMarin, Spiegelman was the senior vice president and chief financial officer at CV Therapeutics. Dan also served as treasurer at Genentech from 1991 to 1998. In addition to their corporate experience, Spiegelman has also worked as an independent biotechnology finance professional.

Dan Spiegelman has a BA in Economics from Stanford University and an MBA from the Stanford University Graduate School of Business.